As clinical research increasingly turns to cellular and immunological endpoints, a site’s ability to process Peripheral Blood Mononuclear Cells (PBMCs) in-house has become a decisive factor in sponsor selection, data quality, and participant experience.
Sequoia Clinical Research has invested in a multi-certified, GCP-compliant PBMC processing laboratory. This paper outlines what that capability is, why it matters, and the concrete advantages it delivers to sponsors, investigators, and the participants who volunteer their time and trust to advance medicine.
| < 6 hrs Sample-to-cryopreservation window |
90%+ Target post-thaw viability standard |
1 Draw Can support multiple downstream assays |
The clinical trial landscape has shifted significantly toward biomarker-driven and cell-based science:
Every one of these modalities depends on one upstream requirement: viable, properly processed PBMCs. A site that cannot isolate and cryopreserve PBMCs on-site, within protocol-specified timeframes, is structurally excluded from this expanding category of research — regardless of how strong its clinical operations are otherwise.
| Capability Area | Without In-House PBMC Lab | With In-House PBMC Lab |
|---|---|---|
| Sample viability | Degrades in transit; variable recovery | Processed within window; high, consistent viability |
| Eligible trial types | Limited to non-cellular endpoints | Immuno-oncology, vaccine, cell/gene therapy, regenerative medicine, biomarker studies |
| Turnaround | Dependent on courier & shipping schedules | Same-day isolation and cryopreservation |
| Participant burden | May require repeat draws | Single draw supports multiple downstream assays |
| Sponsor risk profile | Higher risk of protocol deviations | Lower deviation rate; stronger audit readiness |
| Site competitiveness | Excluded from cell-based-endpoint studies | Eligible for higher-value, higher-acuity trials |
Now, we’ll dive into the benefits of an in-house PBMC lab across the dimensions sponsors, investigators, and participants care about most.
PBMCs start to lose viability and functional activity almost immediately after collection. Samples shipped off-site for processing are exposed to temperature fluctuations, courier delays, and extended time-to-process — all of which introduce variability that can compromise immunogenicity readouts, flow cytometry panels, and functional assays. Processing on-site, within a controlled and verified window, produces higher and more consistent viability, giving sponsors cleaner, more defensible data.
Sponsors and CROs increasingly pre-screen sites for PBMC feasibility before offering study allocations. An accredited, on-site PBMC lab expands the range of studies a site can be selected for — including immuno-oncology, cell and gene therapy, and next-generation vaccine trials — which tend to carry higher per-participant reimbursement and longer, more stable enrollment pipelines.
Because banked PBMCs can support multiple downstream assays from a single collection, participants often face fewer or smaller repeat blood draws over the course of a study. Reliable on-site processing also reduces the chance that a sample is lost in transit and a participant has to be re-contacted or re-drawn — a meaningful quality-of-life benefit for people who have volunteered their time to advance research. Just as importantly, this capability gives local participants access to advanced immunotherapy, vaccine, and cell-therapy trials they might otherwise need to travel to an academic medical center to join.
Eliminating dependence on external couriers not only reduces cost, but also ensures sample stability and shortens the time between collection and usable data. Fewer shipping failures mean fewer repeat visits, fewer deviation reports, and a cleaner regulatory record.
Documented SOPs, calibrated equipment, temperature-monitored storage, and certified laboratory technicians are exactly what sponsor qualification visits and regulatory inspectors look for. A mature PBMC program signals operational integrity across the entire research site — not just in this one capability — and builds the kind of trust that leads to repeat study allocations.
With appropriate participant consent, banked PBMCs can support future ancillary or exploratory research without the need to re-contact and re-draw participants — extending the scientific value of each participant’s contribution while respecting their time.
With an in-house PBMC lab, Sequoia Clinical Research provides sponsors, CROs, and participants a better site experience, helping ensure the delivery of high-quality study data. PBMC processing at Sequoia Clinical Research follows validated, sponsor-auditable standard operating procedures, including:
Sequoia Clinical Research offers a GCP-compliant PBMC processing laboratory equipped with certified clinical research staff, to support the full spectrum of modern immunology-driven trials — from early-phase immuno-oncology studies to large vaccine trials. For sponsors, that means cleaner data and lower operational risk. For participants, it means access to advanced treatment options and a research experience designed around their time and wellbeing.
To learn more about our PBMC processing capabilities, laboratory validation documentation, or current study opportunities, please contact our clinical operations team.